Pay in 4 interest-free payments of $6.21 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
2026 (Current): Launch of the Wegovy pill and the first once-weekly basal insulin ( Awiqli ), further solidifying their cardiometabolic dominance
Safety issues have also been raised on a possible association between incretin-based drugs and pancreatitis or pancreatic cancer based on animal studies and data on patients ( In addition, several effects of incretin-based diabetes therapies beyond their glycemic-lowering properties via the endocrine pancreas have been described, including reduced immune cell infiltration and altered cytokine expression (2)
You tolerated it well
Shift could reflect a changing demand away from oncology toward addressing metabolic disorders GLP1 agonist drugs transformed the weight loss and diabetes landscape in 2023, propelled by robust clinical trial results and a surge in endorsements from celebrities and influencers
Gastric slowing: GLP-1 slows how quickly food leaves your stomach, reducing post-meal glucose spikes and prolonging satiety
